Insight Molecular Diagnostics (IMDX) Cash & Equivalents (2015 - 2026)

Insight Molecular Diagnostics has disclosed Cash & Equivalents across 12 years of filings, most recently posting $28.2 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $28.2 million, down 9.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.2 million (down 9.03% YoY), and the FY2025 annual result was $11.6 million, up 34.12% from the prior year.
• Cash & Equivalents came in at $28.2 million for Q1 2026 at Insight Molecular Diagnostics, up from $11.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $44.8 million in Q2 2022 to a low of $433000.0 in Q4 2022.
• The 5-year median for Cash & Equivalents is $13.8 million (2023), against an average of $17.1 million.
• Across the five-year window, Cash & Equivalents tumbled 98.69% in 2022 and surged 2078.29% in 2023, its largest moves.
• Insight Molecular Diagnostics' Cash & Equivalents stood at $433000.0 in 2022, then soared by 2078.29% to $9.4 million in 2023, then retreated by 8.44% to $8.6 million in 2024, then jumped by 34.12% to $11.6 million in 2025, then surged by 143.47% to $28.2 million in 2026.
• The last three Cash & Equivalents figures came in at $28.2 million (Q1 2026), $11.6 million (Q4 2025), and $18.7 million (Q3 2025), per Business Quant data.